@article {Sarma2020.05.20.20107169, author = {Uddipan Sarma and Bhaswar Ghosh}, title = {Country-specific optimization of testing rates and unlock measures can help to contain COVID19 infection}, elocation-id = {2020.05.20.20107169}, year = {2020}, doi = {10.1101/2020.05.20.20107169}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {In response to the COVID19 outbreak many countries have implemented lockdown to ensure social distancing. However, long lockdowns globally affected the livelihood of millions of people resulting in subsequent unlocks that started a second wave of infection in multiple countries. Unlocking of the economies critically imposes extra burden on testing and quarantine of the infected people to keep the reproduction number (R0) \<1. This, as we demonstrate, requires optimizing a cost-benefit trade-off between testing rate and unlock extent. We delineate a strategy to optimize the trade-off by utilizing a data-trained epidemic model and coupling it with a stochastic agent based model to implement contact tracing. In a country specific manner, we quantitatively demonstrate how combination of unlock and testing can maintain R0 \<1.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding agencies supported the study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not applicableAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDetails of the model simulation and fitting are available upon reasonable request.}, URL = {https://www.medrxiv.org/content/early/2020/09/08/2020.05.20.20107169}, eprint = {https://www.medrxiv.org/content/early/2020/09/08/2020.05.20.20107169.full.pdf}, journal = {medRxiv} }